When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

On August 21, financial news reports that the performance of imeik technology development (300896.SZ) achieved certain growth in the first half of this year, but the growth rate has slowed down significantly compared to before.

Tonight, imeik technology development released its semi-annual report. In the first half of the year, the company achieved operating income of 1.657 billion yuan, a year-on-year increase of 13.53%, and net income attributable to shareholders of listed companies of 1.121 billion yuan, a year-on-year increase of 16.35%.

Looking at the quarterly data, the company's revenue and net income in Q2 only achieved single-digit growth. Among them, the revenue was 0.849 billion yuan, a year-on-year increase of 2.35%; the net income attributable to shareholders was 0.593 billion yuan, a year-on-year increase of 8.03%.

In Q1, imeik technology development achieved revenue of 0.808 billion yuan, a year-on-year increase of 28.24%, and net income of 0.527 billion yuan, a year-on-year increase of 27.38%.

In terms of product types, the gross margin of injectable solution products, which is the main product sector of imeik technology development, centered around 'Hi Body', has declined, and its proportion in total revenue has further decreased. In addition, in addition to the layout of research and development pipelines for botulinum toxin, GLP-1 drugs, imeik technology development is also expanding in the medical beauty equipment field.

Imeik technology development attributes its growth in the semi-annual report to three points: First, the social acceptance of medical beauty services continues to increase, with high industry growth certainty; Second, the significant synergy effect of the company's products reflects the competitive advantages of the product matrix; Third, strengthening brand building and enhancing brand influence.

From the perspective of product types, imeik technology development's revenue mainly comes from solution-type injection products and gel-type injection products with "HiTi" as the core. Among them, solution-type injection products achieved revenue of 97.6 million yuan, an 11.65% increase over the same period last year; gel-type injection products achieved revenue of 64.9 million yuan, a 14.57% increase over the same period last year; In terms of gross margin, the gross margin of solution-type injection products is 93.98%, a year-on-year decrease of 1.12 percentage points, and the gross margin of gel-type injection products is 97.98%, a year-on-year increase of 0.6 percentage points.

In terms of revenue distribution, solution-type injection products account for 58.90% of the total, while gel-type injection products account for 39.17%. Compared with the same period last year, the proportion of solution-type injection products has slightly decreased.

In terms of expenses, imeik technology development's R&D investment in H1 amounted to 126 million yuan, a 20.59% year-on-year increase. During the reporting period, the company made certain achievements in R&D, with registration acceptance for the injection of type A botulinum toxin for moderate to severe glabellar lines and the registration application for minoxidil lotion for hair regeneration. In addition, imeik technology development has R&D pipelines in the areas of Simagel peptide injection solution, injection hyaluronidase, and more.

Furthermore, imeik technology development is continuously expanding its layout in the medical beauty equipment field. On July 24th, imeik technology development announced an increase in capital to control Aimeichuang, raising the company's stake in the latter from 40% to 52% after the capital increase. The capital increase will be completed in two phases, with a total amount of 40 million yuan. It is reported that Aimeichuang owns products such as "Hi Burst Water" hydro dermabrasion device and disposable sterile injection needles.